title: Low-dose regimen of interleukin-2 for metastatic renal carcinoma.
authors.forename: D T
authors.initials: DT
authors.lastname: Sleijfer
authors.forename: R A
authors.initials: RA
authors.lastname: Janssen
authors.forename: P H
authors.initials: PH
authors.lastname: Willemse
authors.forename: A
authors.initials: A
authors.lastname: Martens
authors.forename: L
authors.initials: L
authors.lastname: de Leij
authors.forename: E G
authors.initials: EG
authors.lastname: de Vries
authors.forename: N H
authors.initials: NH
authors.lastname: Mulder
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged
chemical_list: D006680:HLA Antigens; D007376:Interleukin-2